Do analysts prefer MBRX or EXOZ?

Moleculin Biotech presently has a consensus price target of $22.00, indicating a potential upside of 733.33%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, research analysts clearly believe Moleculin Biotech is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, MBRX or EXOZ?

eXoZymes is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moleculin Biotech N/A N/A -$33.56M -$17.98 N/A eXoZymes N/A N/A -$9.16M -$1.14 N/A

Is MBRX or EXOZ more profitable?

Moleculin Biotech's return on equity of 0.00% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A N/A -70.93% eXoZymes N/A -220.63% -141.26%

Does the media favor MBRX or EXOZ?

In the previous week, Moleculin Biotech had 2 more articles in the media than eXoZymes. MarketBeat recorded 3 mentions for Moleculin Biotech and 1 mentions for eXoZymes. eXoZymes' average media sentiment score of 1.43 beat Moleculin Biotech's score of -0.09 indicating that eXoZymes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral eXoZymes 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, MBRX or INKT?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moleculin Biotech N/A N/A -$33.56M -$17.98 N/A MiNK Therapeutics N/A N/A -$12.49M -$2.84 N/A

Is MBRX or INKT more profitable?

Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A N/A -70.93% MiNK Therapeutics N/A N/A -118.57%

Does the media refer more to MBRX or XLO?

In the previous week, Moleculin Biotech had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 3 mentions for Moleculin Biotech and 2 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 0.13 beat Moleculin Biotech's score of -0.09 indicating that Xilio Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Xilio Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, ANVS or MBRX?

Annovis Bio is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annovis Bio N/A N/A -$28.85M -$1.71 N/A Moleculin Biotech N/A N/A -$33.56M -$17.98 N/A

Is ANVS or MBRX more profitable?

Moleculin Biotech's return on equity of 0.00% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -318.08% -215.47% Moleculin Biotech N/A N/A -70.93%

Does the media refer more to ANVS or MBRX?

In the previous week, Moleculin Biotech had 1 more articles in the media than Annovis Bio. MarketBeat recorded 3 mentions for Moleculin Biotech and 2 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 0.00 beat Moleculin Biotech's score of -0.09 indicating that Annovis Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moleculin Biotech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend SCLX or MBRX?

Moleculin Biotech has a consensus target price of $22.00, indicating a potential upside of 733.33%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Moleculin Biotech is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is SCLX or MBRX more profitable?

Moleculin Biotech has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Company Net Margins Return on Equity Return on Assets Scilex -1,110.17% N/A -143.55% Moleculin Biotech N/A N/A -70.93%

Moleculin Biotech (MBRX) Competitors

$2.64 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$2.59 -0.05 (-1.93%)

As of 07/2/2026 07:58 PM Eastern

Compare

MBRX vs. EXOZ, INKT, XLO, ANVS, and SCLX

Should you buy Moleculin Biotech stock or one of its competitors? MarketBeat compares Moleculin Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Moleculin Biotech include eXoZymes (EXOZ), MiNK Therapeutics (INKT), Xilio Therapeutics (XLO), Annovis Bio (ANVS), and Scilex (SCLX). These companies are all part of the "pharmaceutical products" industry.

How does Moleculin Biotech compare to eXoZymes?

Moleculin Biotech (NASDAQ:MBRX) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

15.5% of Moleculin Biotech shares are held by institutional investors. 1.1% of Moleculin Biotech shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Moleculin Biotech presently has a consensus price target of $22.00, indicating a potential upside of 733.33%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, research analysts clearly believe Moleculin Biotech is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Moleculin Biotech has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market. Comparatively, eXoZymes has a beta of 2.73, suggesting that its stock price is 173% more volatile than the broader market.

eXoZymes is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A
eXoZymes	N/A	N/A	-$9.16M	-$1.14	N/A

In the previous week, Moleculin Biotech had 2 more articles in the media than eXoZymes. MarketBeat recorded 3 mentions for Moleculin Biotech and 1 mentions for eXoZymes. eXoZymes' average media sentiment score of 1.43 beat Moleculin Biotech's score of -0.09 indicating that eXoZymes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moleculin Biotech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
eXoZymes	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Moleculin Biotech's return on equity of 0.00% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	N/A	-70.93%
eXoZymes	N/A	-220.63%	-141.26%

Summary

Moleculin Biotech beats eXoZymes on 8 of the 13 factors compared between the two stocks.

How does Moleculin Biotech compare to MiNK Therapeutics?

Moleculin Biotech (NASDAQ:MBRX) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Moleculin Biotech has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A

15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 1.1% of Moleculin Biotech shares are owned by insiders. Comparatively, 20.4% of MiNK Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Moleculin Biotech had 3 more articles in the media than MiNK Therapeutics. MarketBeat recorded 3 mentions for Moleculin Biotech and 0 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 0.00 beat Moleculin Biotech's score of -0.09 indicating that MiNK Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Moleculin Biotech	Neutral
MiNK Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	N/A	-70.93%
MiNK Therapeutics	N/A	N/A	-118.57%

Moleculin Biotech currently has a consensus target price of $22.00, suggesting a potential upside of 733.33%. MiNK Therapeutics has a consensus target price of $35.00, suggesting a potential upside of 199.91%. Given Moleculin Biotech's higher possible upside, analysts clearly believe Moleculin Biotech is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Summary

Moleculin Biotech beats MiNK Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Moleculin Biotech compare to Xilio Therapeutics?

Moleculin Biotech (NASDAQ:MBRX) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Moleculin Biotech presently has a consensus price target of $22.00, indicating a potential upside of 733.33%. Xilio Therapeutics has a consensus price target of $28.00, indicating a potential upside of 206.01%. Given Moleculin Biotech's higher probable upside, research analysts clearly believe Moleculin Biotech is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Moleculin Biotech has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.14, indicating that its share price is 114% less volatile than the broader market.

Moleculin Biotech has higher earnings, but lower revenue than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A
Xilio Therapeutics	$43.77M	1.38	-$35.04M	-$3.55	N/A

Moleculin Biotech has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Moleculin Biotech's return on equity of 0.00% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	N/A	-70.93%
Xilio Therapeutics	-58.52%	-151.42%	-27.61%

15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 1.1% of Moleculin Biotech shares are held by company insiders. Comparatively, 7.5% of Xilio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Moleculin Biotech had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 3 mentions for Moleculin Biotech and 2 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 0.13 beat Moleculin Biotech's score of -0.09 indicating that Xilio Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moleculin Biotech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Xilio Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Moleculin Biotech and Xilio Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Moleculin Biotech compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

Annovis Bio has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market.

In the previous week, Moleculin Biotech had 1 more articles in the media than Annovis Bio. MarketBeat recorded 3 mentions for Moleculin Biotech and 2 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 0.00 beat Moleculin Biotech's score of -0.09 indicating that Annovis Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moleculin Biotech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by company insiders. Comparatively, 1.1% of Moleculin Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Moleculin Biotech's return on equity of 0.00% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-318.08%	-215.47%
Moleculin Biotech	N/A	N/A	-70.93%

Annovis Bio currently has a consensus price target of $13.50, suggesting a potential upside of 597.67%. Moleculin Biotech has a consensus price target of $22.00, suggesting a potential upside of 733.33%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Moleculin Biotech is more favorable than Annovis Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Annovis Bio is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A

Summary

Moleculin Biotech beats Annovis Bio on 7 of the 12 factors compared between the two stocks.

How does Moleculin Biotech compare to Scilex?

Scilex (NASDAQ:SCLX) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Scilex has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market.

Moleculin Biotech has lower revenue, but higher earnings than Scilex. Scilex is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	2.19	-$358.73M	-$40.47	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A

In the previous week, Moleculin Biotech had 3 more articles in the media than Scilex. MarketBeat recorded 3 mentions for Moleculin Biotech and 0 mentions for Scilex. Scilex's average media sentiment score of 0.00 beat Moleculin Biotech's score of -0.09 indicating that Scilex is being referred to more favorably in the media.

Company	Overall Sentiment
Scilex	Neutral
Moleculin Biotech	Neutral

69.7% of Scilex shares are owned by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are owned by institutional investors. 4.5% of Scilex shares are owned by company insiders. Comparatively, 1.1% of Moleculin Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Moleculin Biotech has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,110.17%	N/A	-143.55%
Moleculin Biotech	N/A	N/A	-70.93%

Moleculin Biotech has a consensus target price of $22.00, indicating a potential upside of 733.33%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Moleculin Biotech is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Moleculin Biotech beats Scilex on 10 of the 14 factors compared between the two stocks.

Get Moleculin Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBRX vs. The Competition

Export

Metric	Moleculin Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.09M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-0.15	21.61	28.02	24.70
Price / Sales	N/A	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	0.56	8.66	10.96	6.46
Net Income	-$33.56M	$23.81M	$3.57B	$337.01M
7 Day Performance	-19.27%	3.39%	2.12%	1.69%
1 Month Performance	10.00%	10.81%	5.25%	3.81%
1 Year Performance	-69.83%	62.61%	33.29%	23.90%

Moleculin Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBRX Moleculin Biotech	2.246 of 5 stars	$2.64 flat	$22.00 +733.3%	-69.8%	$14.09M	N/A	N/A	20	Gap Down
EXOZ eXoZymes	0.9156 of 5 stars	$7.23 -6.1%	N/A	-14.4%	$61.31M	$70K	N/A	29	Positive News Gap Down
INKT MiNK Therapeutics	2.4419 of 5 stars	$12.11 -1.8%	$35.00 +189.0%	+69.8%	$60.33M	N/A	N/A	30
XLO Xilio Therapeutics	1.9433 of 5 stars	$9.01 +1.2%	$28.00 +210.8%	-5.7%	$59.24M	$53.48M	N/A	70	Analyst Downgrade
ANVS Annovis Bio	2.4646 of 5 stars	$1.70 -2.6%	$13.50 +696.5%	-18.9%	$58.73M	N/A	N/A	3

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBRX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Moleculin Biotech (MBRX) Competitors

MBRX vs. EXOZ, INKT, XLO, ANVS, and SCLX

How does Moleculin Biotech compare to eXoZymes?

Summary

How does Moleculin Biotech compare to MiNK Therapeutics?

Summary

How does Moleculin Biotech compare to Xilio Therapeutics?

Summary

How does Moleculin Biotech compare to Annovis Bio?

Summary

How does Moleculin Biotech compare to Scilex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX vs. The Competition

Moleculin Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Moleculin Biotech (MBRX) Competitors

MBRX vs. EXOZ, INKT, XLO, ANVS, and SCLX

How does Moleculin Biotech compare to eXoZymes?

Do institutionals and insiders hold more shares of MBRX or EXOZ?

Do analysts prefer MBRX or EXOZ?

Which has more risk & volatility, MBRX or EXOZ?

Which has higher valuation and earnings, MBRX or EXOZ?

Does the media favor MBRX or EXOZ?

Is MBRX or EXOZ more profitable?

Summary

How does Moleculin Biotech compare to MiNK Therapeutics?

Which has more risk and volatility, MBRX or INKT?

Which has stronger valuation and earnings, MBRX or INKT?

Do insiders & institutionals have more ownership in MBRX or INKT?

Does the media refer more to MBRX or INKT?

Is MBRX or INKT more profitable?

Do analysts prefer MBRX or INKT?

Summary

How does Moleculin Biotech compare to Xilio Therapeutics?

Do analysts rate MBRX or XLO?

Which has more volatility and risk, MBRX or XLO?

Which has better valuation & earnings, MBRX or XLO?

Is MBRX or XLO more profitable?

Do institutionals and insiders believe in MBRX or XLO?

Does the media refer more to MBRX or XLO?

Summary

How does Moleculin Biotech compare to Annovis Bio?

Which has more risk and volatility, ANVS or MBRX?

Does the media refer more to ANVS or MBRX?

Do insiders and institutionals hold more shares of ANVS or MBRX?

Is ANVS or MBRX more profitable?

Do analysts prefer ANVS or MBRX?

Which has preferable earnings and valuation, ANVS or MBRX?

Summary

How does Moleculin Biotech compare to Scilex?

Which has more risk and volatility, SCLX or MBRX?

Which has higher earnings & valuation, SCLX or MBRX?

Does the media refer more to SCLX or MBRX?

Do insiders & institutionals have more ownership in SCLX or MBRX?

Is SCLX or MBRX more profitable?

Do analysts recommend SCLX or MBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX vs. The Competition

Moleculin Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools